Karuna Therapeutics director Robert Nelsen disclosed in a filing that he had purchased 200,000 shares of company stock at an average price of $16 per share on July 2. The total transaction value of the purchase was $3,200,000.
Karuna Therapeutics (KRTX) priced 5.578M shares at $16.00. The deal size was increased to 5.58M shares from 4.38M shares and priced within the $15.00-$17.00 range. Goldman Sachs, Citi and Wells Fargo acted as joint book running managers for the offering.